Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RAPP · NASDAQ · Pharmaceutical Preparations
Rapport Therapeutics (RAPP) · oqro.io/stocks/RAPP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$26.15+0.30 (+1.16%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
2 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Oct 28, 2026 · largest single transaction ~$20M
Oct 28, 2026~$20M · 952K sh @ $21.00
DetailsOfficial recordOct 28, 2026~$146K · 6,933 sh @ $21.00
DetailsOfficial recordOct 28, 2026~$134K · 6,395 sh @ $21.00
DetailsOfficial recordInsider buying
5 days before resultsTraded Oct 23 · filed the same day
Since the trade +0.8% · S&P 500 −0.7% · to Nov 13
A Rapport Therapeutics director paid $98K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Abraham Ceesay (Chief Executive Officer) sold ~$64K of Rapport Therapeutics
Planned saleInsider buying
6 days before resultsTraded Oct 22 · filed the same day
Since the trade −1.4% · S&P 500 −1.3% · to Nov 13
A Rapport Therapeutics director paid $974K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 13 months.
Insider buying
6 days before resultsTraded Oct 22 · filed the same day
Since the trade −1.4% · S&P 500 −1.3% · to Nov 13
A Rapport Therapeutics director paid $100K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 13 months.
Traded Oct 22, 2026 · largest single transaction ~$217K
Oct 22, 2026~$217K · 8,239 sh @ $26.38
DetailsOfficial recordInsider buying
6 days before resultsTraded Oct 22 · filed the same day
Since the trade −1.4% · S&P 500 −1.3% · to Nov 13
A Rapport Therapeutics director paid $100K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
7 days before resultsTraded Oct 21 · filed the same day
Since the trade +4.3% · S&P 500 −2.4% · to Nov 13
The CFO of Rapport Therapeutics paid $144K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 19 months.
Abraham Ceesay (Chief Executive Officer) sold ~$108K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$35K of Rapport Therapeutics
Planned saleAbraham N. Ceesay (Officer) plans to sell ~$1.23M of Rapport Therapeutics
Planned, from payCheryl Gault (Chief Operating Officer) sold ~$262K of Rapport Therapeutics
Planned saleCheryl Gault (Chief Operating Officer) sold ~$70K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$76K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$8.6K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$1.8K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$1.04M of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$918K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$38K of Rapport Therapeutics
Planned saleAbraham Ceesay (Chief Executive Officer) sold ~$19K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$122K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$84K of Rapport Therapeutics
Planned saleTraded Sep 12, 2025 · largest single transaction ~$693K
Sep 12, 2025~$334K · 13K sh @ $24.97
DetailsOfficial recordInsider buying
Their first buy on recordTraded Sep 12, 2025 · filed 3 days later
A Rapport Therapeutics director paid $499K out of pocket for Rapport Therapeutics shares. 2 other people at Rapport Therapeutics bought some too, in the same month.
Insider buying
Traded Sep 11, 2025 · filed the same day
A Rapport Therapeutics director paid $79K out of pocket for Rapport Therapeutics shares. 2 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 6 months.
Cheryl Gault (Chief Operating Officer) sold ~$192K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$124K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$3.2K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$119K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$94K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$81K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$81K of Rapport Therapeutics
Planned saleDavid Bredt (Chief Scientific Officer) sold ~$92K of Rapport Therapeutics
Planned saleInsider buying
Traded Mar 12, 2025 · filed 1 day later
The CFO of Rapport Therapeutics paid $100K out of pocket for Rapport Therapeutics shares. 1 other person at Rapport Therapeutics bought some too, in the same month.
Insider buying
Traded Mar 12, 2025 · filed 1 day later
A Rapport Therapeutics director paid $61K out of pocket for Rapport Therapeutics shares. 1 other person at Rapport Therapeutics bought some too, in the same month.
Oct 28, 2026~$79K · 3,772 sh @ $21.00
DetailsOfficial recordOct 22, 2026~$32K · 1,172 sh @ $26.92
DetailsOfficial recordSep 12, 2025~$693K · 28K sh @ $24.50
DetailsOfficial record11 open-market purchases and 8 open-market sales by insiders of RAPP between Feb 8, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 30, 2026. The data provider lists the next release for Mar 8, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Oct 30, 2026 | 11 purchases, 5 sales | None | None |
| Aug 5, 2026 | None | None | None |
| May 7, 2026 | None | None | None |
| Mar 10, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
